Galapagos NV (GLPG) FinancialsGLPGFinancialGalapagos NV

Galapagos NV (GLPG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is R&D, accounting for 96.7% of total sales, equivalent to €127.52M. Another important revenue stream is Fee-for-services. Understanding this composition is critical for investors evaluating how GLPG navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Galapagos NV maintains a gross margin of 25.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -982.92%, while the net margin is 214.26%. These profitability ratios, combined with a Return on Equity (ROE) of 16.26%, provide a clear picture of how effectively GLPG converts its operational activities into shareholder value.

In the context of the broader market, GLPG competes directly with industry leaders such as VIR and NTLA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, GLPG's gross margin of 25.95% stands against VIR's 100.00% and NTLA's 100.00%. Such benchmarking helps identify whether Galapagos NV is trading at a premium or discount relative to its financial performance.

In 2025/Q4, Galapagos reported a very strong quarter with revenue of 900,822,000, up 1093.22% YoY. Net income rose to 782,146,000, up 2990.63% YoY, and EPS reached 11.87, up 3023.68% YoY. Gross margin improved to 99.95%, up 26.28% YoY. The latest quarter season was 2025/Q4, and the reported growth trends are extremely strong on a year-over-year basis.